Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment

References

• Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Moller H. Trends in testicular cancer incidence and mortality in 22 European countries: Continuing increases in incidence and declines in mortality. Int J Cancer 2006; 118:3099–111.
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003;97: 63–70.
   PubMed Web of Science ®Google Scholar
• SWENOTECA. Available from: http://skane.se/sv/Webbplatser/tumorregistret/Patientprocessarbete/Testikelcancer/Vardprogram/.
   Google Scholar
• Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: A review. J Urol 2003;170: 5–11.
   PubMed Web of Science ®Google Scholar
• Nord C, Bjoro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003;44:322–8.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012;30:3752–63.
   PubMed Web of Science ®Google Scholar
• Torp S, Nielsen RA, Fossa SD, Gudbergsson SB, Dahl AA. Change in employment status of 5-year cancer survivors. Eur J Public Health 2013;23:116–22.
   PubMed Web of Science ®Google Scholar
• Marino P, Luis Sagaon T, Laetitia M, Anne-Gaelle le CS. Sex differences in the return-to-work process of cancer survivors 2 years after diagnosis: Results from a large French population-based sample. J Clin Oncol 2013;31:1277–84.
   PubMed Web of Science ®Google Scholar
• Gudbergsson SB, Torp S, Flotten T, Fossa SD, Nielsen R, Dahl AA. A comparative study of cancer patients with short and long sick-leave after primary treatment. Acta Oncol 2011;50:381–9.
   PubMed Web of Science ®Google Scholar
• Lindbohm ML, Taskila T, Kuosma E, Hietanen P, Carlsen K, Gudbergsson S, et al. Work ability of survivors of breast, prostate, and testicular cancer in Nordic countries: A NOCWO study. J Cancer Surviv 2012;6:72–81.
   PubMed Web of Science ®Google Scholar
• Smedby KE. Cancer survivorship and work loss – what are the risks and determinants? Acta Oncol 2014;53: 721–3.
   PubMed Web of Science ®Google Scholar
• Torp S, Nielsen RA, Gudbergsson SB, Fossa SD, Dahl AA. Sick leave patterns among 5-year cancer survivors: A registry-based retrospective cohort study. J Cancer Surviv 2012;6:315–23.
   PubMed Web of Science ®Google Scholar
• Peckham MJ, Bagshaw KD, Blandy JP. Prognostic factors in advanced non-seminatous germ-cell testicular tumours: Results of a multicenter study. Report from the Medical Research Council Working Party on Testicular Tumours. Lancet 1985;1:8.
   PubMed Web of Science ®Google Scholar
• Register SC. Available from: http://www.socialstyrelsen.se/register/halsodataregister/cancerregistret/inenglish.
   Google Scholar
• The Causes of Death Register S. Available from: http://www.socialstyrelsen.se/register/dodsorsaksregistret.
   Google Scholar
• Sweden S. Available from: www.scb.se.
   Google Scholar
• Agency TSI. Available from: http://www.forsakringskassan.se.
   Google Scholar
• Neovius M, Simard JF, Askling J. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann Rheum Dis 2011;70:1010–5.
   PubMed Web of Science ®Google Scholar
• Taskila T, Martikainen R, Hietanen P, Lindbohm ML. Comparative study of work ability between cancer survivors and their referents. Eur J Cancer 2007;43:914–20.
   PubMed Web of Science ®Google Scholar
• Taskila T, Lindbohm ML. Factors affecting cancer survivors’ employment and work ability. Acta Oncol 2007;46: 446–51.
   PubMed Web of Science ®Google Scholar
• Bottcher HM, Steimann M, Ullrich A, Rotsch M, Zurborn KH, Koch U, et al. Work-related predictors of not returning to work after inpatient rehabilitation in cancer patients. Acta Oncol 2013;52:1067–75.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 2010;28:4649–57.
   PubMed Web of Science ®Google Scholar
• Joly F, Heron JF, Kalusinski L, Bottet P, Brune D, Allouache N, et al. Quality of life in long-term survivors of testicular cancer: A population-based case-control study. J Clin Oncol 2002;20:73–80.
   PubMed Web of Science ®Google Scholar
• Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354–65.
   PubMed Web of Science ®Google Scholar
• Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 2008;18:121–31.
   PubMed Web of Science ®Google Scholar
• Skoogh J, Steineck G, Stierner U, Cavallin-Stahl E, Wilderang U, Wallin A, et al. Testicular-cancer survivors experience compromised language following chemotherapy: Findings in a Swedish population-based study 3–26 years after treatment. Acta Oncol 2012;51:185–97.
   PubMed Web of Science ®Google Scholar
• Sprauten M, Brydoy M, Haugnes HS, Cvancarova M, Bjoro T, Bjerner J, et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol 2014;32:571–8.
   PubMed Web of Science ®Google Scholar
• Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012;30:300–7.
   PubMed Web of Science ®Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56.
   PubMed Web of Science ®Google Scholar
• Ibrahim A, Zambon E, Bourhis JH, Ostronoff M, Beaujean F, Viens P, et al. High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Eur J Cancer 1993;29A:1398–403.
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Baars JW, Schornagel JH, Vlasveld LT, Mandjes I, Pinedo HM, et al. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 1992;3:855–60.
   PubMed Web of Science ®Google Scholar